As RNA therapeutics evolve far beyond their vaccine origins, a new generation of scientists and manufacturers is rethinking how to produce these complex medicines safely, efficiently, and at scale.

As the Australian market winds down for the holiday season, with a slight dip attributed to profit-taking and global indices nearing record highs, investors are reflecting on their portfolios and ...

ExploRNA Therapeutics’ biologically inspired, ground-breaking technologies are enabling more precise customization of mRNA constructs with advanced vaccine and therapeutic applications. Research based ...

PYC Therapeutics Limited ( ($AU:PYC) ) has shared an announcement. PYC Therapeutics has issued 2,000,000 unlisted options to director Peter ...

Cofactor Genomics, a commercial-stage diagnostics company transforming precision oncology through RNA-based predictive tests, today announced strategic investments from Labcorp and Ascension Ventures.

Death cap mushrooms (Amanita phalloides) are among the world’s most poisonous fungi, responsible for the majority of fatal ...

Researchers in Beijing have generated a transcriptomic atlas comparing human fetal tooth germs from the upper and lower jaws at the critical cap stage of development. Previous studies of tooth ...

With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...

If 2026 is the year smaller-cap FTSE 250 stocks head back into the limelight, it could pay to find some good-value candidates ...

Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.

On December 16, Julian Emanuel, Senior Managing Director at Evercore ISI, shared his outlook on the equity market and the ...